ruxolitnib
| Name | Value |
|---|---|
| Weight | 306.373 g/mol |
| Zinc ID | ZINC43207851 |
| Smiles | N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1 |
| Molecular formula | C17H18N6 |
| Mode of inhibition | Direct JAK1 and JAK2; Tyrosin kinase inhibitor |
| CAS | 941678-49-5 |
Clinical Trials
| Study title | Status | Conditions | Link |
|---|---|---|---|
| Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation | Not yet recruiting | Accelerated/Blast-phase Myeloproliferative Neoplasm|Chronic-phase Myelofibrosis|IDH2 Mutation | NCT04281498 |
References
| Publication | DOI | Pubmed | PMCID |
|---|
Vendors
| Company | Lnk to product |
|---|---|
| Tocris | https://www.tocris.com/products/ruxolitinib_7064 |
| MedChemExpress | https://www.medchemexpress.com/Ruxolitinib.html |
| Selleckchem | https://www.selleckchem.com/products/INCB18424.html |
| Caymanchemicals | https://www.caymanchem.com/product/11609/ruxolitinib |
| Adooq | https://www.adooq.com/s-ruxolitinib.html |
Filter data
| Compound | ruxolitnib | Experiment types | Concentrations | Cell lines | Organisms | Animal models | STAT proteins | Other |
Experiments
| Compound | Experiment type | Investigated event | Concentration | Cell line | Organism | Animal model | Stat protein | Details |
|---|